ANXA9 ELISA kit
- Known as:
- ANXA9 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ANXA9-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ANXA9 ELISA kit
Related genes to: ANXA9 ELISA kit
- Gene:
- ANXA9 NIH gene
- Name:
- annexin A9
- Previous symbol:
- ANX31
- Synonyms:
- -
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-11
- Date modifiied:
- 2016-10-05
Related products to: ANXA9 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ANXA9 ELISA kit
- Colorectal cancer (CRC) represents a major public health challenge [...]. - Source: PubMed
Publication date: 2025/11/18
Zeng Shi-JieHe KeShi Zhi - Ulcerative colitis (UC) is a life-threatening heterogeneous condition characterized by inflammation of the colon. Endoplasmic reticulum aminopeptidase 1 (ERAP1) is essential for antigen processing and immune regulation, however, its specific role in UC pathogenesis and therapeutic response remains unclear. This study aimed to investigate the role of ERAP1 in the response to sulfasalazine, a standard treatment for UC, using an ERAP1-heterozygous (ERAP1) mouse model susceptible to colitis. - Source: PubMed
Publication date: 2025/09/05
Riaz BushraRyu Hye-MyungIslam S M ShamsulBabita RaharSeong Je KyungLee HoLee Eunjoo HSohn Seonghyang - Colorectal cancer (CRC) is a major global health challenge, creating an urgent need to find new biomarkers that improve early detection and treatment success. While studies suggest that ANXA9 contributes to cancer development, its expression in CRC and its links to prognosis, immune evasion, and resistance are poorly understood. - Source: PubMed
Publication date: 2025/09/01
Hong MingyangDong QianZhu HuimingHuang Xu - This study intended to figure out the effects of fixed effects and genes such as beta-lactoglobulin (β-LG), prolactin (PRL), annexin A9 (ANXA9), and acetyl-CoA acyltransferase 2 (ACAA2) on the structure of fatty milk acids in Awassi ewes, as well as any potential genotype-genotype interactions. - Source: PubMed
Publication date: 2025/03/25
Jawasreh Khaleel IKhrais DanaAlu'datt MuhammadHaddad Nizar JAwabdeh SamiAlMadani Mohammad IsamBrake MohamadAl-Araishi Mohamad AhmadSadder MontherAl-Amareen Ahmad - Chemoresistance and tumor recurrence remain major obstacles in colorectal cancer (CRC) therapy. Elucidating the molecular mechanisms underlying treatment resistance is critical for improving therapeutic outcomes. : We analyzed transcriptomic profiles from public datasets (TCGA and GSE39582) to identify differentially expressed genes associated with a poor response to neoadjuvant chemotherapy in CRC patients. Among 298 candidate genes, emerged as significantly overexpressed in chemoresistant tumors and associated with a poor prognosis. These findings were further validated in an independent cohort of 146 Stage III CRC patients using immunohistochemistry and survival analysis. The expression of was evaluated in oxaliplatin acquired-resistant CRC cell lines via qPCR and Western blot. Functional studies, including RNA interference, colony formation, apoptosis assays, and drug sensitivity testing, were performed in vitro and in vivo to assess the role of . A high-throughput drug screen identified G749, a inhibitor, as a potential therapeutic agent. expression was significantly elevated in non-responders to chemotherapy and oxaliplatin-resistant CRC cell lines. The knockdown of reduced proliferation and enhanced oxaliplatin sensitivity. G749 was found to suppress expression in a dose-dependent manner and inhibit CRC cell growth in vitro and in patient-derived organoids. In a CRC xenograft mouse model, G749 reduced the tumor burden without observable toxicity. Mechanistically, we identified as a transcriptional regulator of . ChIP-qPCR confirmed binding to the promoter, especially in resistant cells. Silencing suppressed tumor cell growth and restored chemosensitivity. The signaling axis drives chemoresistance and tumor progression in CRC. inhibition by G749 effectively downregulates and sensitizes tumors to chemotherapy, highlighting a novel therapeutic approach for chemoresistant CRC. - Source: PubMed
Publication date: 2025/05/20
Lin DezhengXu YuchengZhan HuanmiaoLiang YufanLiu RiyunLiu JunLuo DandongChen XiaochuanCai JiaweiZou Yifeng